AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20046552
Drug: Manual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual treatment technique (4-minute pain-alleviating traction) 3 segments away from the concordant segment
Trial: 15102867
Drug: Parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 40 mg bid IV for 6 days with UFH on day 5 (n = 18)
Trial: 15102867
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) alone (n = 18)
Trial: 12122123
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment for Charcot's arthropathy; specific intervention details not provided.
Trial: 7783654
Drug: Vasodilator administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasodilator administration (prazosin and hydralazine) alone or in combination with a beta‐blocker (propranolol)
Trial: 7783654
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (vasodilators + propranolol)
Trial: 2295294
Drug: Loxiglumide (CCK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (CCK antagonist), 800 mg (two tablets of 400 mg each)
Trial: 381006
Drug: (‐)eburnamonine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (‐)eburnamonine (80 mg/day for the first 5 days, then 60 mg/day for at least 20 days)
Trial: 381006
Drug: Nicergoline (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline (20 mg/day for the first 5 days, then 15 mg/day for at least 20 days)
Trial: 7013976
Drug: Doxorubicin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (300 mg/kg)
Trial: 7013976
Drug: Cycloleucine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycloleucine (300 mg/kg)
Trial: 7013976
Drug: Cycloleucine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycloleucine (200 mg/kg)
Trial: 28762160
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy for children with ASD
Trial: 28762160
Drug: All parents
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All parents (including treatment and control)
Trial: 26106962
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination formulation
Trial: 22695489
Drug: Almorexant (evening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almorexant (evening administration)
Trial: 17526469
Drug: Olanzapine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10-20 mg/d) with diet modifications (500 kcal/d less than usual) and moderate physical activity (jogging lightly for 30 min 3 times a week)
Trial: 17526469
Drug: Olanzapine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10-20 mg/d) only
Trial: 15583924
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT) with HELBO Blue and TheraLite laser
Trial: 12297170
Drug: Aprotinin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (2 x 10(6) KIU loading dose and 0.5 x 10(6) KIU/h during surgery, n=22)
Trial: 12297170
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (control, n=25)
Trial: 383287
Drug: High-dose methanol
RxNorm normalized name: methanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methanol extraction residue fraction of Bacillus Calmette-Guérin (MER) (2.0 mg)
Trial: 383287
Drug: Low-dose methanol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methanol extraction residue fraction of Bacillus Calmette-Guérin (MER) (0.5 mg)
Trial: 383287
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution placebo
Trial: 26200180
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (insulin treatment if glucose >150 mg/dl)
Trial: 21801540
Drug: Neostatin (lipid-lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostatin (lipid-lowering drug)
Trial: 19855033
Drug: Therapy status
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy status
Trial: 9449397
Drug: Ang I
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ang I infusion
Trial: 9449397
Drug: Ang II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ang II infusion
Trial: 7831698
Drug: Dextrorphan (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrorphan (loading dose 60 to 150 mg, maintenance infusion maximum total dose 3310 mg)
Trial: 7831698
Drug: Dextrorphan (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrorphan (loading dose 145 to 260 mg, maintenance infusion 30 to 70 mg/h)
Trial: 2194442
Drug: Systemic corticosteroids
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic corticosteroids (high dose, short term)
Trial: 25072647
Drug: Topical dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dorzolamide 2% and timolol 0.5% twice daily postoperatively until gas dissolution
Trial: 22947356
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg to 20 mg daily
Trial: 22947356
Drug: Lisinopril 10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10 mg to 40 mg daily
Trial: 22947356
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg to 20 mg + Lisinopril 10 mg to 40 mg
Trial: 16130176
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of nemifitide administered by standard needle/syringe
Trial: 16130176
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of nemifitide administered by needle-free injection
Trial: 16130176
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of nemifitide administered by needle-free injection
Trial: 7072313
Drug: acebutolol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acebutolol (400 mg/die)
Trial: 7072313
Drug: diuretic mefrusid
RxNorm normalized name: mefruside
DrugBank: Mefruside (DB13405)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diuretic mefrusid (25 mg/die)
Trial: 7072313
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of acebutolol and mefrusid
Trial: 30567753
Drug: Ibrutinib (560
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (560 or 840 mg daily) combined with high-dose methotrexate (HD-MTX) at 3.5 g/m2 every 2 weeks for a total of 8 doses (4 cycles) and rituximab.
Trial: 27155289
Drug: Labels containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labels containing 'tsp' or 'teaspoon' units (alone or with 'mL')
Trial: 27155289
Drug: Labels containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labels containing 'mL' only
Trial: 27155289
Drug: Labels with
RxNorm normalized name: Albumin, blood serum, labeled with iodine-125
DrugBank: Albumin iodinated I-125 serum (DB09429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labels with 'teaspoon' and 'mL'
Trial: 27155289
Drug: Labels with
RxNorm normalized name: Albumin, blood serum, labeled with iodine-125
DrugBank: Albumin iodinated I-125 serum (DB09429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labels with 'tsp' and 'mL'
Trial: 16263089
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of delta-opioid receptors (DOR) and kappa-opioid receptors (KOR) in skin tissues
Trial: 11867377
Drug: Physostigmine 2
RxNorm normalized name: PHYSostigmine 2 mg/5 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine 2 mg IV
Trial: 3904820
Drug: Acyclovir (excluding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (excluding prior antiviral treatment)
Trial: 3904820
Drug: Adenine arabinoside
RxNorm normalized name: Adenine
DrugBank: Adenine (DB00173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenine arabinoside (excluding prior antiviral treatment)
Trial: 16793623
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg estradiol benzoate injected intramuscularly
Trial: 12657225
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (GH) administered for 3 months
Trial: 11080706
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) 400 microg administered twice daily
Trial: 11080706
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) 800 microg administered twice daily
Trial: 9475305
Drug: Subcutaneous jet-injection
RxNorm normalized name: Jet Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous jet-injection of recombinant human growth hormone (rhGH)
Trial: 9475305
Drug: Conventional needle-injection
RxNorm normalized name: NEEDLES,INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional needle-injection of recombinant human growth hormone (rhGH)
Trial: 7714412
Drug: Insulin eyedrops
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin eyedrops (50 microliters of sterile normal saline containing varying insulin concentrations)
Trial: 7714412
Drug: Insulin eyedrops
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin eyedrops (100 U/ml in saline)
Trial: 7714412
Drug: Insulin eyedrops
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin eyedrops
Trial: 2455115
Drug: Chlorthalidone 25
RxNorm normalized name: chlorthalidone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25 mg q.d. added to nifedipine 20 mg b.i.d.
Trial: 2455115
Drug: Placebo q.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo q.d. added to nifedipine 20 mg b.i.d.
Trial: 27893474
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly squat exercises with whole-body vibration
Trial: 26994090
Drug: Ceftolozane/tazobactam 1.5
RxNorm normalized name: ceftolozane/tazobactam 1.5 gram INTRAVEN VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftolozane/tazobactam 1.5 g every 8 hours for 7 days
Trial: 26994090
Drug: Levofloxacin 750
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750 mg once daily for 7 days
Trial: 25450083
Drug: Probiotic VSL#3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic VSL#3 (9 × 10^11 bacteria) daily for 6 months
Trial: 22956006
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg twice daily for 2 days)
Trial: 20795923
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus inspiratory muscle training using a threshold device, with an initial load of 30% of their maximal inspiratory pressure, increased by 10% daily, administered for 5 min, twice a day, 7 days a week from the commencement of weaning until extubation.
Trial: 18773749
Drug: Pharmacological treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatments (3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors, fibric acid derivatives, insulin sensitizers, cannabinoid receptor type 1 blockers)
Trial: 8008680
Drug: Propranolol and
RxNorm normalized name: propranolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol and Acebutolol therapy
Trial: 26037324
Drug: Optimised usual
RxNorm normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised usual care (medication review by psychiatrist/geriatrician)
Trial: 23814044
Drug: TCH (six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCH (six cycles of docetaxel plus carboplatin combined with trastuzumab administered for 1 year)
Trial: 23814044
Drug: AC→TH (adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC→TH (adjuvant doxorubicin and cyclophosphamide followed by docetaxel plus trastuzumab administered for 1 year)
Trial: 19249413
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Hydrochlorothiazide and Atenolol
Trial: 15090706
Drug: Sauna therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sauna therapy (60 degrees C far infrared-ray dry sauna for 15 minutes followed by bed rest with a blanket for 30 minutes once a day for two weeks)
Trial: 11146706
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alendronate and naproxen
Trial: 9783096
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ECT
Trial: 9783096
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ECT
Trial: 2555187
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 mg intravenously, followed by a continuous infusion of 10 mg.h-1)
Trial: 25352655
Drug: SAXA (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAXA (5 mg/day) plus DAPA (10 mg/day) on background MET (≥1,500 mg/day)
Trial: 25352655
Drug: SAXA (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAXA (5 mg/day) plus MET
Trial: 25352655
Drug: DAPA (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPA (10 mg/day) plus MET
Trial: 19669251
Drug: TACE +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE + thymalfasin (1.6 mg SC, 5 times weekly)
Trial: 14970093
Drug: Ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250 mg twice daily orally for 3 days followed by placebo for 4 days (3-day group, 93 patients)
Trial: 14970093
Drug: Ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250 mg twice daily orally for 7 days (7-day group, 90 patients)
Trial: 12243820
Drug: Sucralfate (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (3 g in 15 mL suspension) administered rectally
Trial: 12243820
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same suspension without sucralfate) administered rectally
Trial: 12243820
Drug: Rectal pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal pain of moderate or severe grade during RT
Trial: 9678787
Drug: gemfibrozil (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemfibrozil (600 mg b.d.)
Trial: 9678787
Drug: bezafibrate mono
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate mono (400 mg daily)
Trial: 2566637
Drug: Azidothymidine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azidothymidine therapy
Trial: 25588784
Drug: Low-dose dexamethasone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexamethasone (0.2 to 0.9 mg twice daily)
Trial: 24014208
Drug: Sesame lignans
RxNorm normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sesame lignans (50 mg, sesamin/episesamin=1/1)
Trial: 11832182
Drug: Anticoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy after operation in group A
Trial: 11832182
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group B (no anticoagulation therapy)
Trial: 9443614
Drug: FAN regimen:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAN regimen: fluorouracil 500 mg/m2, doxorubicin 50 mg/m2 on day 1, escalating doses of vinorelbine (15, 20, 25, 30 mg/m2) on days 1, 8, and 15 every 3 weeks.
Trial: 9443614
Drug: SUPERFAN regimen:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUPERFAN regimen: fluorouracil 340 mg/m2 and folinic acid 200 mg/m2 on days 1-5, doxorubicin 40 mg/m2 on day 1, escalating doses of vinorelbine (15, 20, 25, 30 mg/m2) on day 1 and again on day 5 every 4 weeks.
Trial: 3953330
Drug: Treatment prescribed
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment prescribed to 52 incontinent residents
Trial: 30869167
Drug: Perampanel 2-12
RxNorm normalized name: perampanel 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel 2-12 mg/day
Trial: 29516701
Drug: Intradermal needle‐embedding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal needle‐embedding therapy (once every other day for 20 days)
Trial: 29516701
Drug: Conventional medicines,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medicines, neuromuscular electrical stimulation of the bilateral midlines of the neck and swallowing function training
Trial: 12243439
Drug: Sweep gas
RxNorm normalized name: sheep wool preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweep gas flow at 1.60 l/min/m2 (Group 2)
Trial: 12243439
Drug: Sweep gas
RxNorm normalized name: sheep wool preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweep gas flow at 2.0 l/min/m2 (Group 3)
Trial: 12243439
Drug: Sweep gas
RxNorm normalized name: sheep wool preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweep gas flow at 1.35 l/min/m2 (Group 1)
Trial: 2152844
Drug: Calcium (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1000 mg/d) and cholecalciferol (25 micrograms/d) supplementation
Trial: 417361
Drug: Piracetam 9.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam 9.6 g/day
Trial: 27651506
Drug: Crushed intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed intranasal Morphine ARER
Trial: 27651506
Drug: Intact Morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact Morphine ARER
Trial: 25546166
Drug: Canagliflozin/metformin (150/1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet administered in fed state
Trial: 25546166
Drug: Canagliflozin/metformin (150/1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet administered in fasted state
Trial: 21237212
Drug: Acipimox (Aci)
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (Aci) administered 1h before exercise (45 min, 2 W/kg of lean body mass)
Trial: 21237212
Drug: Acipimox (Aci)
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (Aci) administered 1h before exercise
Trial: 19217443
Drug: Hyperinsulinemic-euglycemic (H-E)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic-euglycemic (H-E) clamp with porcine or human insulin (40 mU/[m(2) min])
Trial: 19217443
Drug: Porcine vs
RxNorm normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine vs human insulin
Trial: 15784036
Drug: Octreotide 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 300 mug, b.i.d. plus midodrine 7.5 mg, t.i.d.
Trial: 11915786
Drug: ephedrine 6
RxNorm normalized name: pseudoephedrine 6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ephedrine 6 mg (Group E‐6)
Trial: 11915786
Drug: ephedrine 12
RxNorm normalized name: ePHEDrine 12.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ephedrine 12 mg (Group E‐12)
Trial: 7722706
Drug: Atole (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atole (high protein and energy supplement)
Trial: 1779513
Drug: Corinfar (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corinfar (20 mg)
Trial: 1779513
Drug: Hypothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothiazide (50 mg)
Trial: 1779513
Drug: Anapriline (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anapriline (80 mg)
Trial: 7240596
Drug: Urushiol oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urushiol oil injections